Biosimulation Market: Growth, Size, Share, and Trends

Report Code HIT 3629
Published in Oct, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029

Market Growth Outlook Summary

The global biosimulation market growth forecasted to transform from USD 4.24 billion in 2024 to USD 9.18 billion by 2029, driven by a CAGR of 16.7%. The market is experiencing significant growth, driven by increasing R&D investments in the pharmaceutical and biotech industries. Biosimulation facilitates the drug discovery and development process through predictive modeling of biological systems, making it easier to evaluate a drug’s safety and efficacy. This approach reduces drug discovery time and costs by minimizing experimental work and optimizing clinical trial design. AI-integrated biosimulation platforms, such as Orion by OpenEye, Cadence Molecular Sciences, and the BIOiSIM platform by VeriSIM Life, offer enhanced accuracy and efficiency, leading to improved predictions in drug development.

Biosimulation Market – Global Forecast and Key Opportunities to 2029

Asia Pacific

The Asia Pacific biosimulation market is experiencing significant growth driven by rising R&D investments and a growing burden of chronic diseases. Budget constraints push healthcare providers to adopt cost-effective solutions, while the region's expanding biotechnology sector is further enhancing the demand for biosimulation tools.

Advancements in quantitative systems pharmacology (QSP) help build better biosimulation models to drive the market significantly.

Emerging applications of biosimulation in precision medicine, biopharmaceuticals, and toxicology are expected to provide lucrative opportunities for market players.

The North America market is expected to be worth USD 3.21 billion by 2029, growing at a CAGR of 14.4% during the forecast period.

The absence of standardized protocols for biosimulation model representation poses a challenge for collaboration and scalability, limiting market growth opportunities.

Biosimulation Market Dynamics to 2029

DRIVER: Growing adoption of biosimulation software by regulatory bodies

Regulatory agencies around the world, like the US FDA, the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), use biosimulation software to improve drug safety and evaluate effectiveness. These tools help to speed up the drug approval process by identifying any sort of potential issues with the new drugs, which saves time and cost involved in the process. In December 2021, the US FDA renewed and expanded its licenses for Certara's biosimulation software, now holding over 400 user licenses for Simcyp and Phoenix software. This expansion allowed the FDA to simulate drug behavior in virtual patient populations, to assess potential drug-drug interactions, and predict adverse effects more effectively. Additionally, the EMA has endorsed in silico approaches to streamline drug evaluations, contributing to the growing market demand for these technologies.

RESTRAINT: Data Availability and Quality

The effectiveness of biosimulation models heavily depend on the quality and comprehensiveness of the data used to develop them. Insufficient or low-quality data can result in unreliable predictions and incorrect simulations. The required chemical, biological, or clinical data is often incomplete or unavailable, especially in the case of rare diseases or novel drug compounds. For instance, if clinical trial data from earlier phases is incomplete or if real-world data (RWD) lacks proper validation, then the biosimulation outcomes may not accurately give real-world drug performance. When tapping such scenarios, the authenticity of the data used is of prime importance. Established market players often have access to large datasets and libraries of data, but for newer players entering the market, it is challenging to get access to such databases, requiring large investments in the initial phase.

 

OPPORTUNITY: Use of biosimulation solution for pediatric drug development

Pediatric populations are very different from adults in physiology and drug responses, which complicates clinical trial design. Biosimulation bridges this gap with virtual models that simulate drug interactions in children at various developmental stages and reduce the need for extensive clinical trials. For instance, Simcyp Pediatric by Certara is a platform that allows researchers to model pharmacokinetics and pharmacodynamics (PK/PD) by inputting the variables such as age and weight, to optimize the dosing and predict adverse effects. Recently, the FDA published an “Integrate-Simulate-Optimize” workflow for employing Model-Informed Drug Development (MIDD), which emphasizes understanding disease pathophysiology and extrapolating data from adult populations or other pediatric groups to enhance pediatric drug development efforts.

CHALLENGES: Difficulty in matching the complexity of biological systems and processes

Matching the complexity of biological systems and processes is a major challenge for the simulators and modelers. This is because biological processes are complex structures with many pathways interrelating to one another. Biological systems are dynamic in nature; hence, they can change rapidly in response to various stimuli, making it difficult to develop adaptive models that accurately predict long-term outcomes. The individual variability in genetics and physiology adds another layer of complexity to this challenge. Generating a high-fidelity simulation requires significant computational resources, which increases the need for advanced infrastructure. A successful biosimulation relies on effective collaboration between biologists, mathematicians, and computer scientists, but this interdisciplinary collaboration may sometimes pose a challenge as well.

Biosimulation Market Map & Ecosystem Overview

The biosimulation ecosystem includes software providers, pharmaceutical and biotech companies, regulatory agencies, academic institutions, and contract research organizations (CROs). The interaction among these players shapes the development, adoption, and advancement of biosimulation technologies.

The key stakeholders in this market include Healthcare IT Service Providers, Biosimulation Vendors, Clinical Research Organizations, Pharmaceutical/Biopharmaceutical Companies, Research and Development (R&D) Companies, Business Research and Consulting Service Providers, Medical Research Laboratories, Academic Medical Centers/Universities/Hospitals, Regulatory Agencies, Clinical Researchers, Clinical Research Organizations, Investors and Venture Capitalists.

Solution providers in the market develop and cater biosimulation software and services, such as PBPK, PK/PD simulation software, molecular modeling and simulation software, toxicity prediction software, and trial design software, based on the customer’s requirements, whereas the services offered consist of consulting & advisory, implementation, training & support, and data analysis & interpretation services.

Source: Secondary Literature, Interviews with Experts, and MarketsandMarkets Analysis

 

The global biosimulation market is segmented on the basis of offering, application, therapeutic area, revenue model, deployment model, end user, and region.

By offering, the software segment accounted for the largest share of the biosimulation market in 2023

By offering, the biosimulation market is segmented into software and services. The software segment held the largest share of the biosimulation market in 2023. This segment is categorized into standalone modules and integrated software suites/platforms. The standalone platforms are divided into molecular modeling & simulation software, PBPK modeling & simulation software, PK/PD modeling & simulation software, clinical trial simulation software, toxicity prediction software, and other biosimulation software.

The large share of the software segment can be attributed to the extensive efforts of pharmaceutical and biotech companies in drug discovery and development. More and more companies are putting efforts and capital into drug discovery. As of 2023, the US FDA approved a total of 55 new drugs, including 17 biologics, 9 TIDES (5 peptides and 4 oligonucleotides), and 29 small molecules. The use of biosimulation accelerates the drug discovery & development process while reducing the associated costs. According to the JAMA Network, the R&D cost for developing a new drug is estimated to range from USD 314 million to USD 4.46 billion. Use of biosimulation and modeling tools help improve the overall efficiency of the drug discovery and development process.

Oncology segment to hold the largest share in the biosimulation market by therapeutic area

Based on therapeutic area, the Biosimulation market is segmented into oncology, cardiovascular disease, neurological disorders, infectious diseases and other therapeutic areas. The oncology market dominated the biosimulation market in 2023 and is poised to grow significantly during the forecast period. The World Health Organization, in 2022, stated around 20 million new cancer cases and 9.7 million deaths, highlighting the need for effective therapies. Biosimulation is of critical importance as scientists and researchers can now model tumor biology and predict drug response and dosing regimens for chemotherapy, targeted therapies, and immunotherapies. As of October 2024, the US FDA has approved a total of 48 drugs and therapies for oncology/hematologic malignancies. The FDA, in this regard, has also launched an initiative called Project Optimus aimed at reforming dose optimization and selection in oncology drug development to enhance both the efficacy and safety profiles of novel therapies. This project promotes early cooperation between drug developers and the FDA in an improved communication, workshops, and data-driven strategy to carry out effective dose-finding evaluations. The players like Certara, Cellworks, OpenEye, Cadence Molecular Sciences are further focusing on the discovery and development of safer cancer therapies.

The on-premises model accounted for the largest share of the biosimulation market in 2023, by deployment type

Based on the deployment model, the biosimulation market is segmented into on-premises, cloud-based, and hybrid models. On-premises biosimulation models are driven by several key factors that cater to the specific needs of organizations. Data security is a significant concern, as many companies prefer to maintain control over sensitive information to comply with regulatory requirements and protect intellectual property. Additionally, on-premises solutions allow for extensive customization to fit unique organizational workflows, providing greater flexibility in model development.

However, cloud-based models are set to record the fastest growth during the forecast period owing to its scalability, providing ease of access to the users without heavy upfront investments in infrastructure. Some of the software offering cloud-based deployment include Phoenix by Certara, Maestro by Schrödinger, BIOVIA by Dassault Systèmes, and Orion by OpenEye, Cadence Molecular Sciences.

North America accounted for the largest share of the Biosimulation market in 2023

The biosimulation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America accounted for the highest share of the biosimulation market. This was driven by the strong biopharmaceutical sector, particularly in the US, where leading pharmaceutical and biotech companies increasingly adopt advanced modeling techniques to enhance drug discovery and development process. The region also witnesses a dominating presence of the majority of market players like Certara, Simulations Plus, Schrödinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group ULC., Rosa & Co. LLC., and Genedata AG, among others. The pharmaceutical and biotechnology companies are investing a large share of their revenue in the expansion of their R&D capabilities, thus driving the demand for biosimulation tools in the region.

Moreover, the regulatory agencies like FDA are embracing biosimulation technologies in clinical studies. Collaborative efforts among academia, industry, and regulatory bodies further strengthens its application. The FDA through various initiatives, such as the Model-Informed Drug Development (MIDD) Paired Meeting Program, focuses on integrating exposure-based, biological, and statistical models into drug development and regulatory processes to enhance decision-making and optimize therapeutic outcomes.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION

Biosimulation Market Recent Developments and Insights

  • In October 2024, Certara acquired Chemaxon to combine its expertise in biosimulation with Chemaxon's cheminformatics expertise. This acquisition will help Certara expand its capabilities to help life science companies enhance their productivity and boost scientific innovation success rates.
  • In September 2024, Advanced Chemistry Development (ACD/Labs) launched the version 2024 of its flagship Percepta platform, offering enhanced prediction accuracy for logP, logD, and pKa, and a range of ADME and toxicity endpoints, making the platform more robust and efficient.
  • In June 2024, Simulations Plus acquired Pro-ficiency, LLC, in a USD 100 million deal to expand its market reach. This acquisition tends to double Simulations Plus’s total addressable market to USD 8 billion by utilizing Pro-ficiency's AI-driven software and services.
  • In March 2024, Dassault Systèmes collaborated with CDR-Life Inc. to enhance the development of highly tumor-selective immunotherapies using CDR-Life’s M-gager platform. This collaboration allowed the contract research team of Dassault to perform virtual “what if” experiments on antibody-based biologics utilizing the BIOVIA software and CDR-Life’s experimental data.

Key Players Driving Growth in the Biosimulation Market

Want to explore hidden markets that can drive new revenue in Biosimulation Market?

Scope of the Report

Report Metric Details
Market size available for years 2022–2029
Base Year Considered 2023
Forecast period 2024–2029
Forecast units Million/Billion (USD)
Segments covered Offerings, Applications, Therapeutic Area, Revenue Model, Deployment Model, and End-user
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East Africa

Key Questions Addressed by the Report

The global biosimulation market is projected to grow from USD 4.24 billion in 2024 to USD 9.18 billion by 2029, demonstrating a robust CAGR of 16.7%.
Primary drivers for the biosimulation market include increasing R&D investments in pharmaceutical and biotech industries, and the growing adoption of biosimulation software by regulatory bodies to improve drug safety and efficacy.
The oncology therapeutic area holds the largest share of the biosimulation market, driven by the need for improved therapies and the increasing use of biosimulation in cancer drug development.
Challenges in the biosimulation market include the difficulty in matching the complexity of biological systems and processes, and issues with data availability and quality, especially for rare diseases or novel drug compounds.
North America accounted for the largest share of the biosimulation market in 2023, driven by the strong biopharmaceutical sector and increasing adoption of advanced modeling techniques in drug development.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biosimulation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
16
EXECUTIVE SUMMARY
27
PREMIUM INSIGHTS
45
MARKET OVERVIEW
67
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 INDUSTRY TRENDS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - MATHEMATICAL MODELING
    - SOFTWARE PLATFORMS
    - QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP)
    COMPLEMENTARY TECHNOLOGIES
    - DATA ANALYTICS
    - MACHINE LEARNING AND AI
    ADJACENT TECHNOLOGIES
    - IN SILICO TRIALS
  • 5.6 PORTER'S FIVE FORCE ANALYSIS
  • 5.7 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY ANALYSIS
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR THE BIOSIMULATION MARKET
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.10 KEY CONFERENCES & EVENTS 2024-2025
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN THE BUYING PROCESS
    BUYING CRITERIA
  • 5.12 UNMET NEEDS/END USER EXPECTATIONS IN BIOSIMULATION MARKET
  • 5.13 ECOSYSTEM MAPPING
  • 5.14 CASE STUDY ANALYSIS
  • 5.15 TRENDS/DISRUPTION IMPACTING CUSTOMER’S BUSINESS
  • 5.16 BIOSIMULATION MARKET, INVESTMENT AND FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI IN BIOSIMULATION MARKET
BIOSIMULATION MARKET, BY OFFERING
78
  • 6.1 INTRODUCTION
  • 6.2 SOFTWARE
    STANDALONE MODULES
    - MOLECULAR MODELING & SIMULATION SOFTWARE
    - PBPK MODELING & SIMULATION SOFTWARE
    - PK/PD MODELING & SIMULATION SOFTWARE
    - CLINICAL TRIAL SIMULATION SOFTWARE
    - TOXICITY PREDICTION SOFTWARE
    - OTHER BIOSIMULATION SOFTWARE
    INTEGRATED SOFTWARE SUITES/PLATFORM
  • 6.3 SERVICE
    CONSULTING & ADVISORY
    IMPLEMENTATION, TRAINING & SUPPORT
    DATA ANALYSIS & INTERPRETATION
BIOSIMULATION MARKET, BY APPLICATION
89
  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & VALIDATION
    LEAD IDENTIFICATION & OPTIMIZATION
  • 7.3 DRUG DEVELOPMENT
    PRECLINICAL TESTING
    - PK/PD
    - ADME/TOXICOLOGY
    CLINICAL TRIALS
    - PHASE I
    - PHASE II
    - PHASE III
    - PHASE IV/POST-MARKETING SURVEILLANCE
  • 7.4 DISEASE MODELING
  • 7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
    PRODUCTION PLANNING & OPTIMIZATION
    QUALITY CONTROL & PROCESS MONITORING
    DEMAND FORECASTING & INVENTORY MANAGEMENT
    RISK MANAGEMENT & CONTINGENCY PLANNING
    OTHERS (IF ANY)
  • 7.6 OTHER APPLICATIONS
BIOSIMULATION MARKET, BY THERAPEUTIC AREA
98
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
  • 8.3 CARDIOVASCULAR DISEASE
  • 8.4 NEUROLOGICAL DISORDERS
  • 8.5 INFECTIOUS DISEASE
  • 8.6 OTHERS (IF ANY)
BIOSIMULATION MARKET, BY REVENUE MODEL
116
  • 9.1 INTRODUCTION
  • 9.2 LICENSE-BASED MODEL
  • 9.3 SUBSCRIPTION-BASED MODEL
  • 9.4 SERVICE-BASED MODEL
  • 9.5 PAY-PER-USE MODEL
BIOSIMULATION MARKET, BY DEPLOYMENT MODEL
135
  • 10.1 INTRODUCTION
  • 10.2 ON-PREMISES MODEL
  • 10.3 CLOUD-BASED MODEL
  • 10.4 HYBRID MODEL
BIOSIMULATION MARKET, BY END-USER
156
  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 11.4 ACADEMIC & RESEARCH INSTITUTIONS
  • 11.5 REGULATORY BODIES
  • 11.6 OTHERS (IF ANY)
BIOSIMULATION MARKET, BY REGION
169
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    US
    CANADA
    NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.3 EUROPE
    GERMANY
    FRANCE
    UK
    SPAIN
    ITALY
    REST OF EUROPE
    EUROPE: MACROECONOMIC OUTLOOK
  • 12.4 ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    REST OF ASIA PACIFIC
    ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.5 LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
    LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 12.6 MIDDLE EAST AND AFRICA
    GCC COUNTRIES
    REST OF MIDDLE EAST & AFRICA
    MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
COMPETITIVE LANDSCAPE
188
  • 13.1 OVERVIEW
  • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 13.6 VALUATION AND FINANCIAL METRICS OF KEY BIOSIMULATION VENDORS
  • 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - OFFERING FOOTPRINT
    - APPLICATION FOOTPRINT
    - END-USER FOOTPRINT
  • 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 13.9 COMPETITIVE SCENARIO AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    OTHERS
COMPANY PROFILES
198
  • 14.1 KEY PLAYERS
    CERTARA, USA.
    SIMULATIONS PLUS.
    DASSAULT SYSTÈMES
    SCHRÖDINGER, INC.
    ADVANCED CHEMISTRY DEVELOPMENT, INC.
    CHEMICAL COMPUTING GROUP ULC.
    ROSA & CO. LLC.
    GENEDATA AG (A DANAHER COMPANY)
    PHYSIOMICS PLC.
    IN SILICO BIOSCIENCES.
    ALLUCENT.
    OPENEYE SCIENTIFIC (A CADENCE MOLECULAR SCIENCES COMPANY)
    CELLWORKS GROUP, INC.
    VERISIM LIFE.
    NETABOLICS SRL
  • 14.2 CHARNWOOD DISCOVERY
    THE MATHWORKS, INC.
CHARNWOOD DISCOVERY
202
ANSYS, INC
  • 15.1 OTHER PLAYERS
    INSTEM GROUP OF COMPANIES
    INSILICO MEDICINE
    SCM – SOFTWARE CHEMISTRY & MATERIALS
    BIOSYMETRICS, INC.
    ATOMWISE INC.
    INSITRO.
    CLINITHINK.
APPENDIX
215
  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 16.3 AVAILABLE CUSTOMIZATIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS

The study involved significant activities to estimate the current size of the Biosimulation market. Exhaustive secondary research was done to collect information on the biosimulation market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the biosimulation market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering biosimulation solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of biosimulation vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the biosimulation market.

After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of Biosimulation solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of Primary Participants:

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the Biosimulation market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Biosimulation is a computer-aided mathematical modeling to simulate the functioning of the human body and analyze the effects of drugs, both beneficial and adverse. By creating a virtual model of physiological processes, researchers can investigate disease progression and evaluate the potential impact of various therapeutic interventions. This technology enables the simulation of real-world biological interactions, facilitating the testing of multiple scenarios and optimizing the development of safer, more effective drugs and treatments.

Stakeholders

  • Biosimulation Vendors
  • Contract Research Organizations
  • Pharmaceutical/Biopharmaceutical Companies
  • Research and Development (R&D) Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers/Universities/Hospitals
  • Government Agencies
  • Regulatory Agencies
  • Clinical Researchers
  • Clinical Research Organizations
  • Investors and Venture Capitalists

Report Objectives

  • To define, describe, and forecast the biosimulation market based on offerings, applications, therapeutic area, revenue model, deployment model, end user, and region
  • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
  • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
  • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
  • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
  • To profile the key players and comprehensively analyze their market sizes and core competencies
  • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

Previous Versions of this Report

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) & Geography

Report Code HIT 3629
Published in Oct, 2024, By MarketsandMarkets™

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022

Report Code HIT 3629
Published in Jan, 2018, By MarketsandMarkets™

Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)

Report Code HIT 3629
Published in Jul, 2015, By MarketsandMarkets™

Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)

Report Code PH 1301
Published in Oct, 2012, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biosimulation Market

DMCA.com Protection Status